Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
Revive Therapeutics (RVV.CN), a specialty life sciences company, on Thursday announced that the U.S. Food and Drug Administration has assigned it a meeting date of June 7. Revive had requested a meeti
MT NewswiresApr 18 07:57 ET
Express News | Revive Therapeutics Ltd - Meeting Date Assigned by FDA Is June 7, 2024
Moomoo 24/7Apr 18 07:02 ET
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
GlobeNewswireMar 27 09:08 ET
Revive Therapeutics To Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID
TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
GlobeNewswireMar 19 07:00 ET
Revive Therapeutics Provides Corporate Update
Yahoo FinanceMar 12 07:00 ET
Mind Medicine Sends Psychedelic Stocks Higher After FDA Status for LSD Formulation
Seeking AlphaMar 7 11:29 ET
Oregon House Passes Bill to End Hard Drug Decriminalization
There are many factors in setting drug policy, which often center around the benefits or detriments to a society and its economy.
Seeking AlphaMar 1 06:42 ET
Psychedelic Stocks Gain After FDA Priority Review for MDMA Therapy
Seeking AlphaFeb 12 12:13 ET
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
GlobeNewswireFeb 1 07:30 ET
Revive Therapeutics Announces Offering of up to $3 Million
Seeking AlphaJan 25 04:10 ET
Revive Says Phase 3 Trial for Oral COVID Drug Failed
Seeking AlphaJul 6, 2023 07:05 ET
Revive Therapeutics Spikes After Update on Oral COVID-19 Drug
Seeking AlphaApr 19, 2023 11:58 ET
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin
BenzingaApr 5, 2023 09:58 ET
FDA Asks Revive to Amend Main Goals of Phase 3 Trial for COVID Drug
Seeking AlphaMar 8, 2023 08:20 ET
Revive Therapeutics to Submit Updated Information for Phase 3 COVID Drug Trial Endpoints
Seeking AlphaJan 12, 2023 13:58 ET
Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders
Life sciences company Revive Therapeutics Ltd. (OTCQB:RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction. The company closed a private placement deal — with
Benzinga Real-time NewsJan 12, 2023 13:12 ET
Revive Therapeutics Raises $4.3M From Private Placement
Seeking AlphaJan 12, 2023 06:55 ET
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials
Life sciences biotech Psyence Group Inc. (OTCQB:PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million). The company issued more than 7.
Benzinga Real-time NewsDec 16, 2022 16:47 ET
Revive Therapeutics To Raise Up To $5M Via Private Placement
REVIVE THERAPEUTICS LTD. (OTCQB:RVVTF) (CSE:RVV) announced that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per unit;. The offerin
Benzinga Real-time NewsDec 1, 2022 09:34 ET
Psychedelic Stock Gainers And Losers From November 30, 2022
GAINERS:ATAI Life Sciences (NASDAQ:ATAI) shares closed up 11.71% at $3.53Compass Pathways (NASDAQ:CMPS) shares closed up 7.63% at $10.30Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.28% at $0.8
Benzinga Real-time NewsNov 30, 2022 16:31 ET
No Data
No Data